Why This Matters

7-hydroxymitragynine (7-OH) is the most potent alkaloid found in kratom—and it’s become the center of a regulatory storm that’s forcing shop owners to rethink their kratom category entirely.

If you’re stocking high-concentration 7-OH products, you need to know this: the FDA recommended Schedule I placement in July 2025, Florida banned it outright in August 2025, and multiple Kratom Consumer Protection Act (KCPA) states now cap 7-OH at 2% of total alkaloid content. That effectively bans the concentrated extracts, shots, and capsules that have been flying off shelves.

This isn’t a hypothetical compliance issue. It’s happening now, state by state, and the product mix that worked six months ago may expose you to significant legal risk today.

What Is 7-Hydroxymitragynine?

7-OH is one of over 40 alkaloids naturally present in kratom leaf (Mitragyna speciosa). It occurs at trace levels in whole-leaf kratom—typically less than 0.02% by dry weight—but it’s responsible for much of kratom’s opioid-receptor activity.

Manufacturers discovered they could isolate and concentrate 7-OH to create products with 10%, 20%, even 50% 7-OH content. These concentrated extracts, often sold as shots, tablets, or enhanced powders, became popular with customers looking for stronger effects than traditional kratom powder delivers.

The problem: regulators and legislators view concentrated 7-OH as a fundamentally different product than whole-leaf kratom. While many states have adopted KCPA frameworks to regulate natural kratom, they’re drawing a hard line against synthetic or highly concentrated alkaloid products.

7-OH vs. Whole-Leaf Kratom: The Regulatory Split

Understanding this distinction is critical for compliance:

Whole-leaf kratom contains mitragynine (the primary alkaloid, typically 1-2% by weight) and trace amounts of 7-OH. It’s regulated under KCPA in 18+ states, which impose lab testing, labeling, age verification, and adulterant bans—but allow the product to remain on shelves.

Concentrated 7-OH products are treated as adulterated or synthetic in many jurisdictions. Even if the 7-OH is extracted from natural kratom, the concentration process creates a product that regulators consider outside the bounds of traditional botanical commerce.

Kratom legality is changing faster than almost any other category in the smoke shop space. Here’s where things stand as of mid-2026.

States with Full Kratom Bans

These states ban all kratom products, including whole-leaf and 7-OH:

  • Alabama
  • Arkansas
  • Connecticut
  • Indiana
  • Kansas (effective July 2026)
  • Louisiana
  • Michigan
  • Vermont
  • Wisconsin
  • Tennessee (pending governor signature)

California has a de facto commercial ban via California Department of Public Health administrative action (October 2025). It’s not a legislative ban, but it effectively prohibits the sale of kratom and 7-OH products statewide.

Do not stock kratom or 7-OH in these states. The risk isn’t worth it.

States with Specific 7-OH Bans or Concentration Caps

Florida banned 7-OH outright via emergency rule in August 2025. Whole-leaf kratom remains legal, but any product containing concentrated or isolated 7-OH is prohibited.

KCPA states with 2% alkaloid caps include Arizona, Oklahoma, Colorado, Texas, and Utah. These states regulate kratom but cap 7-OH at 2% of total alkaloid content. That means:

  • Traditional kratom powder and leaf: legal
  • Low-concentration extracts within the 2% limit: legal
  • High-concentration 7-OH shots and tablets: banned

The 2% cap is a de facto ban on the concentrated products most vendors are selling as “7-OH” or “extract” SKUs.

Eighteen-plus states have passed KCPA legislation, which creates a regulated framework for kratom sales. Requirements typically include:

  • Age verification (21+ in most states)
  • Product registration and labeling standards
  • Third-party lab testing for contaminants and alkaloid content
  • Prohibition on adulterated, synthetic, or fortified products
  • Prohibition on health claims

Check your state’s specific KCPA rules. Some allow broader alkaloid ranges; others impose strict caps that eliminate high-concentration products.

Rhode Island reversed its kratom ban effective April 1, 2026, under its own KCPA framework. If you’re in RI, you can now stock kratom—but only compliant, tested, properly labeled product.

Federal Status: Unscheduled but Under Review

Kratom and its alkaloids are not currently scheduled under the Controlled Substances Act. However, the FDA recommended Schedule I placement for concentrated 7-OH in July 2025, citing overdose reports and concerns about potency.

The DEA has not acted on that recommendation. That means 7-OH remains federally legal—but the window may be closing. If the DEA moves to emergency scheduling, you could have 30 days or less to clear inventory.

What This Means for Your Store

Compliance Risk Is High

If you stock 7-OH products, you’re operating in a gray zone that’s shrinking by the quarter. State-level enforcement is inconsistent, but when it does happen, the consequences include product seizure, fines, and in some cases criminal liability.

Your compliance checklist:

  1. Verify your state’s current kratom status. Don’t rely on what was true six months ago. Check your state health department, attorney general, or controlled substances board for updates.
  2. Review product labels and lab reports. If you’re in a KCPA state, make sure every kratom SKU has third-party testing documentation and compliant labeling. If you’re in a 2% cap state, confirm the 7-OH concentration is within legal limits.
  3. Ask your distributor for documentation. Reputable kratom vendors provide certificates of analysis (COAs) showing alkaloid content, heavy metals, microbials, and contaminants. If your supplier can’t provide this, find a new supplier.
  4. Monitor news and trade groups. The American Kratom Association (AKA) tracks legislative activity. Subscribe to their alerts or join a regional smoke shop trade group that monitors state-level changes.

Margin and Stocking Considerations

High-concentration 7-OH products typically carry strong margins—40% to 60% in many markets—and they move fast. That’s why they became a staple in smoke shops.

But margin doesn’t matter if you’re holding unsellable inventory after a ban.

If you’re in a legal or KCPA state, whole-leaf kratom powder and capsules remain strong sellers with lower compliance risk. They won’t deliver the same per-unit margin as concentrated shots, but they’re far less likely to become illegal overnight.

If you’re in a 2% cap state, you can still stock low-concentration extracts—but verify alkaloid levels with your distributor. Many products marketed as “enhanced” or “extract” exceed the 2% threshold.

If you’re in a ban state or considering high-concentration products, the risk-reward calculation has shifted. Holding five cases of 7-OH shots in a state that’s one legislative session away from a ban is a gamble.

Alternatives to Consider

Shop owners pulling back on 7-OH are looking at adjacent categories to fill the gap:

Whole-leaf kratom (powder, capsules, tea) remains legal in KCPA states and delivers consistent repeat business. Customer education is key—many buyers aren’t familiar with strain types (red, green, white) or dosing.

Kava products are seeing strong growth, especially among customers who used kratom for relaxation or social use. Kava is a completely different plant (Piper methysticum, a legal root from the South Pacific) with no federal or state scheduling issues. It’s sold as powder, capsules, shots, teas, and gummies. Kava bars are also emerging as a retail format in some markets.

Kava brings in a different customer—often someone looking for a legal, non-intoxicating social beverage—but there’s overlap with the kratom buyer base. If you’re losing 7-OH SKUs, kava is worth testing.

CBD and hemp-derived cannabinoids continue to perform well in smoke shops, and they’re a natural adjacency for kratom customers seeking relaxation or wellness products.

What to Watch

The kratom category is in flux. Here’s what to monitor over the next 6-12 months:

  • DEA action on the FDA’s Schedule I recommendation. If the DEA moves to emergency scheduling for 7-OH, it will happen fast. Have a plan to clear inventory.
  • State legislative sessions. Expect more states to introduce kratom bills—some will be KCPA-style regulation, others will be outright bans. Track bills in your state and neighboring states if you operate multiple locations.
  • KCPA concentration caps spreading. The 2% cap model is gaining traction. If you’re in a KCPA state without a cap today, it may be added via amendment.
  • Enforcement activity. State boards of pharmacy, health departments, and attorneys general are increasing enforcement. Pay attention to cease-and-desist letters, product seizures, and prosecutions in your region.
  • Supplier consolidation. As compliance requirements increase, smaller kratom vendors are exiting the market. Expect fewer suppliers, but higher-quality documentation and testing from those that remain.

Actionable Takeaways

  • Audit your inventory today. Identify which products contain 7-OH and at what concentration. Cross-reference with your state’s current kratom law.
  • Get documentation from your suppliers. COAs, alkaloid profiles, and compliance statements should be standard. If your vendor can’t provide them, that’s a red flag.
  • Don’t stock kratom in ban states. The legal risk outweighs any margin, no matter how strong the customer demand.
  • Test kava if you’re scaling back kratom. It’s a legal, growing category with a similar customer profile and fewer compliance headaches.
  • Educate your staff. Make sure your counter team understands the difference between whole-leaf kratom and concentrated 7-OH, and can answer customer questions about legality and availability.
  • Consult a compliance attorney if you’re uncertain. State-level kratom law is complex and evolving. If you operate in multiple states or carry significant kratom inventory, legal counsel is worth the investment.

FAQ

What is 7-hydroxymitragynine?

7-hydroxymitragynine (7-OH) is a naturally occurring alkaloid found in trace amounts in kratom leaf. It’s the most potent compound in kratom, responsible for much of its opioid-receptor activity. Concentrated 7-OH products amplify this alkaloid to 10% or higher, creating a product that regulators increasingly view as distinct from traditional whole-leaf kratom.

Is 7-hydroxymitragynine legal to sell?

It depends on your state. 7-OH is not federally scheduled, but the FDA recommended Schedule I placement in July 2025. Florida banned it outright in August 2025. Several KCPA states cap 7-OH concentration at 2% of total alkaloid content, effectively banning high-concentration products. Always verify your state’s current law before stocking.

What’s the difference between kratom and 7-OH products?

Whole-leaf kratom contains a full spectrum of alkaloids, with mitragynine as the primary component and 7-OH in trace amounts. Concentrated 7-OH products isolate or amplify the 7-OH alkaloid to create a stronger, more potent product. Regulators treat concentrated 7-OH as adulterated or synthetic, even if derived from natural kratom.

Which states have banned 7-OH specifically?

Florida has an outright 7-OH ban (August 2025). Arizona, Oklahoma, Colorado, Texas, and Utah cap 7-OH at 2% of total alkaloid content under their KCPA laws, which effectively bans high-concentration products. Additionally, all states with full kratom bans (Alabama, Arkansas, Connecticut, Indiana, Kansas, Louisiana, Michigan, Vermont, Wisconsin, and California via administrative action) prohibit 7-OH.

What should I stock instead of high-concentration 7-OH products?

If you’re pulling back on concentrated 7-OH, consider whole-leaf kratom powder and capsules in KCPA-compliant states, kava products (powder, shots, gummies), and hemp-derived CBD or cannabinoid products. These categories offer lower compliance risk and appeal to similar customer bases.